Our proprietary technology enables biotech and pharmaceutical partners to streamline the development of highly specific, effective, and novel antibody therapeutics.
Source-reported As recorded 2026-09-23
Browser storage is unavailable. Keep this page open and export your collection before leaving.
Biotech pharma
Macromoltek
Overview
Macromoltek: Revolutionizing antibody design.
Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
Company description As recorded 2026-11-08
Product & workflow
Founders & team
Monica Berrondo
Founder/CEOMonica Berrondo, Ph.D., is an entrepreneur, scientist, and software engineer. Her expertise lies in antibody structure-prediction and analysis, protein functional analysis, protein mutational analysis, and computational approaches to complex scientific problems.
Founder profile As recorded 2026-09-15
Susana Kaufmann
Founder/CTOFounder profile As recorded 2026-09-15
14team members reported
Source-reported As recorded 2026-09-15
Founded 2010 · Source
News & product activity
Cohort membership
Winter 2018Winter 2018
Original evidence ↗Sources & observations
Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedAustin, TX, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-11
- Product visualsNot documented
- Founders & originsTeam information
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2018 Q1 (quarter only)
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
Similar businesses
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
- Founded
- 2024
- Team
- 15 people
Same product type · Infrastructure
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
- Founded
- 2025
- Team
- 4 people
Same product type · Infrastructure
BioStack is building the data engine for healthcare and drug discovery AI. The bottleneck is not models. It is access to high-quality biological data. Clinical and experimental data is fragmented, unstructured, and locked inside…
Founders · Product
- Founded
- 2025
- Team
- 9 people
Same product type · Infrastructure
Transform scattered lab data into structured insights. Labric automatically captures instrument data, enables AI-powered analysis, and saves research teams hundreds of hours.
Founders · Product · How it works
- Founded
- 2025
- Team
- 6 people
Same product type · Infrastructure
What if we made as many cancer drugs next year as we have in the last decade?
Founders · Product
- Founded
- 2025
- Team
- 4 people
Same product type · Infrastructure
Spatial proteomics from H&E and multimodal patient data imputation. Lattice predicts spatially resolved protein-marker maps from routine H&E slides as virtual multiplex immunofluorescence (mIF) channels, transforming incomplete patient…
Founders · Product · How it works
- Founded
- 2025
- Team
- 2 people
Same product type · Infrastructure